BRAF gene mutation in wild-type KRAS patients with colorectal cancers;Mutación del gen BRAF en pacientes con cánceres de colon y recto con KRAS no mutado

Revista Medica de Chile

Volumn 142, Issue 1, 2014, Pages 55-60

  Roa, Iván ^a   Game, Anakaren ^b   Bizama, Carolina ^a   Schalper, Kurt ^c  

^a Creative Bioscience   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

^c YALE UNIVERSITY   (United States)

Author keywords

Colonic neoplasms; Mutation; Proto Oncogene Proteins B raf; Proto Oncogene Proteins p21 (ras)

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; CANCER STAGING; COLORECTAL TUMOR; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MUTATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84901022973     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872014000100009     Document Type: Article

References (39)

1. The International Agency for Research on Cancer. Globocan. http://www.iarc.fr/en/media-centre/iarc-news/2011/globocan2008-prev.php 2008.
2. http://deis.minsal.cl/index.asp. 2012.
3. Zárate AJ, Alonso FT, Garmendia ML, López-Kostner F. Increasing crude and adjusted mortality rates for colo-rectal cancer in a developing South American country. Colorectal Dis 2013; 15 (1): 47-51.
4. (http://deis.minsal.cl/vitales/vitales2010/Serie_Mortali-dad_causa_Chile_2000_2010/Chile.htm). 2010.
5. Bacolod MD, Barany F. Molecular profling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 2011; 18 (13): 3694-700.
6. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
7. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69(10): 4286-93.
8. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007; 3 (11): e225.
9. Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004; 10 (12 Pt 1): 4015-21.
10. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008; 105 (11): 4283-8.
11. Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, et al. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis 2012; 27(5): 657-63.
12. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26 (35): 5705-12.
13. Allegra CJ, Jessup JM, Somerfeld MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27 (12): 2091-6.
14. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26 (7): 823-33.
15. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, et al. KRAS gene amplifcation in colorectal cancer and impact on response to EGFR-targeted therapy 10.1002/ijc.28106. Int J Cancer 2013.
16. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? An-ticancer Agents Med Chem 2012; 12 (2): 163-71.
17. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modifcation by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154 (1): 37-49.
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Mo-linari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical beneft to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4 (10): e7287.
19. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62 (22): 6451-5.
20. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63 (17): 5209-12.
21. Deng G, Bell I, Crawley S, Gum J, Terdiman J P, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10 (1 PART 1): 191-5.
22. Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, et al. MLH1 Promoter Methylation Frequency in Colorectal Cancer Patients and Related Clinicopathological and Molecular Features. PLoS One 2013; 8 (3): e59064.
23. Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer 2013; 4 (4): 320-2.
24. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clini-copathological relevance of BRAF mutations in human cancer. 10.1097/PAT.0b013e328360b61d. Pathology 2013.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418 (6901): 934.
26. Govender D, Chetty R. Gene of the month: BRAF. J Clin Pathol 2012; 65 (11): 986-8.
27. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10 (3): 385-94.
28. Dienstmann R, Tabernero J. BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011; 11 (3): 285-95.
29. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101 (4): 715-21.
30. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining beneft from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27 (35): 5924-30.
31. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. 10.1038/bjc.2013.118. Br J Cancer 2013.
32. Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today 2012; 42 (11): 1037-45.
33. Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. The role of EGFR monoclonal antibodies (MoABs) cetuximab/ panitumab, and BRAF inhibitors in BRAF mutated co-lorectal cancer. J Gastrointest Oncol 2013; 4 (1): 72-81.
34. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorec-tal carcinoma: Pathologic aspects. J Gastrointest Oncol 2012; 3 (3): 153-73.
35. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. 2009.24.6116. J Clin Oncol 2010; 28 (7): 1254-61.
36. English DR, Young J P, Simpson JA, Jenkins MA, Southey MC, Walsh MD, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008; 17 (7): 1774-80.
37. Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhathat S. Somatic Mutations of K-Ras and BRAF in Thai Colorectal Cancer and their Prognostic Value. Asian Pac J Cancer Prev 2013; 14 (1): 329-32.
38. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011; 11 (6): 635-42.
39. Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, et al. Recommendations from the EGAPP Working Group: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? 10.1038/gim.2012.184. Genet Med 2013.